VEGFA and neoplasm: Tyrosine kinase inhibitors (TKIs) serve as first-line treatments for advanced hepatocellular carcinoma, obstructing tumor angiogenesis by blocking signaling pathways such as vascular endothelial growth factor (VEGF) (12, 13).